
Natco Pharma Ltd: Valuation Shifts Signal Changing Price Attractiveness Amid Sector Dynamics
2026-11-17 08:00:08Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, signalling a notable change in price attractiveness. This article analyses the recent valuation metrics, compares them with peer averages, and examines the implications for investors amid evolving market dynamics.
Read More
Natco Pharma Ltd. is Rated Sell by MarketsMOJO
2026-11-13 10:10:45Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 November 2026, providing investors with the latest insights into the company’s fundamentals, returns, and market standing.
Read More
Natco Pharma Ltd. is Rated Sell by MarketsMOJO
2026-11-02 10:10:25Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read More
Natco Pharma Ltd. is Rated Sell by MarketsMOJO
2026-10-22 10:10:26Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 4 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read More
Natco Pharma Ltd. Falls to 52-Week Low of Rs 780 as Sell-Off Deepens
2026-10-15 09:40:20For the third consecutive session, Natco Pharma Ltd. has seen its share price decline, culminating in a fresh 52-week low of Rs 780 on 15 Oct 2026. This downward momentum has dragged the stock below all key moving averages, signalling persistent selling pressure despite a broader market that is showing signs of resilience.
Read More
Natco Pharma Ltd. is Rated Sell by MarketsMOJO
2026-10-11 10:10:15Natco Pharma Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 October 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Natco Pharma Ltd. Technical Momentum Shifts to Bearish Amid Market Pressure
2026-10-08 08:00:22Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. This change is underscored by deteriorating signals across key technical indicators including MACD, RSI, Bollinger Bands, and moving averages, reflecting growing market caution despite the company’s resilient price levels relative to broader indices.
Read More
Natco Pharma Ltd. Technical Momentum Shifts Amid Mixed Market Signals
2026-10-06 08:00:44Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend. Despite a marginal day change of 0.05% with the stock closing at ₹822.15, the technical indicators present a complex picture that investors should carefully analyse before making decisions.
Read MoreAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
20-Nov-2026 | Source : BSEPress Release regarding the receipt of Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) Inspection at our Visakhapatnam Andhra Pradesh Finished Dosage Formulations (FDF) Unit
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
18-Nov-2026 | Source : BSEQ2FY27 Earnings Conference Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16-Nov-2026 | Source : BSEIntimation of Investor Meet
Corporate Actions
No Upcoming Board Meetings
Natco Pharma Ltd. has declared 62% dividend, ex-date: 19 Nov 26
Natco Pharma Ltd. has announced 2:10 stock split, ex-date: 26 Nov 15
No Bonus history available
Natco Pharma Ltd. has announced 2:21 rights issue, ex-date: 01 Oct 26
